41 results about "Daytime somnolence" patented technology

Pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed. Pharmaceutical compositions comprising tizanidine and modafinil are disclosed. Methods for reducing somnolence, sleepiness, lethargy, dizziness, drowsiness, somnolence, tiredness, lightheadedness, increased weakness, confusion, unsteadiness, clumsiness, or a combination of the symptoms thereof in a human patient; treating pain; and attenuating muscle spasticity, using pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed.

A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by C_max below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml. The composition provides pulsatile release of milnacipran to produce a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.

The invention generally relates to compositions and methods with covalently bound compounds, such as controlled substances covalently attached to a chemical moiety, and opioid antagonists or covalently bound opioid antagonists to enhance analgesic potency and/or attenuate one or more adverse effects of covalently bound compounds, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence), physical dependence or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of a covalently bound compound and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of a covalently bound compound. The methods of the invention comprise administering to a subject an analgesic or sub-analgesic amount of a covalently bound compound and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of a covalently bound compound and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of covalently bound compound. The invention also relates to the addition of covalently-bound opioid antagonists to the compositions containing covalently bound compounds such that if the compositions are subjected to manipulation by illicit chemists, the opioid antagonist is released effectively reducing or eliminating the euphoric effect of the covalently bound compounds.

The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.

The invention discloses a novel Chinese medicinal composition for curing somnolence and a preparation method thereof. The Chinese medicinal composition mainly comprises the following raw material medicaments: tangerine peel, immature bitter orange, raw raidx astragali, white paeony root, Chinese angelica, common yam rhizome, campanumaea pilosula, ginseng, motherwort herb, storax, nutgrass galingale rhizome, camphor, Szechwan Chinaberry Fruit, chrysanthemum, salvia miltiorrhiza bunge, fineleaf schizonepeta herb, divaricate saposhnikovia root, incised notopterygium rhizome, medicated leaven, malt, radish seed, peach seed, safflower, south dodder seed, twotooth achyranthes root and the like. The Chinese medicinal composition can be prepared into any common oral preparation by the conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms such as somnolence, drowsiness, cataplexy, sleep paralysis, hypnoagogic hallucination and the like. The Chinese medicinal composition has the advantages of exact clinical effect, obvious curative effect, quick response, low cost, basically no toxic or side effect and the like because the Chinese medicinal composition is basically combined by edible and pharmaceutical medicaments specified in national formulary.

The present invention provides a method and pharmaceutical composition for preventing or treating the development of syndromes related to dysfunctional energy metabolism, such as neuropathy, spontaneous nocturnal muscle cramps associated with neuropathy, seizuring, diabetes mellitus; pediatric hypoglycemia; myopathy; muscle fatigue; muscle spasms; somnolence; reduced mental acuity; exercise intolerance and myocardial insufficiency, which are due to cofactor deficiencies associated with the pyruvate dehydrogenase complex and the alpha-ketogluterate dehydrogenase (a-ketogluterate dehydrogenase) complex in humans or other mammals in need thereof. In particular, a method of preventing or treating at least one syndrome related to defective glucose metabolism in humans or other mammals is provided comprised of administering a combination of enzyme cofactors containing therapeutically effective amounts of thioctic acid, niacinamide, pantothenate, riboflavin and thiamine. Also provided is a pharmaceutical composition comprised of a carrier and the combination of cofactors.

Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment wherein the drug is an antihistamine, retention of the antihistamine at the nasal mucosa is improved and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced. By making a dry powder formulation of an antihistamine (e.g., azelastine) having an average particle size of between 10 and 20 microns, the antihistamine is restricted primarily to the desired target organ, the nasal mucosa. Because the active ingredient stays in the nasal region, a lower dose can be used to achieve the same desired effect. As demonstrated by the examples, this lower dose reduces the incidence of somnolence, and because the active ingredient remains at the target organ and does not accumulate in the back of the throat and mouth, this formulation does not impart a bitter taste.

The invention relates to a methylphenidatefrozen dry powder preparation for injection and a preparation process thereof; the preparation takes the salt of the methylphenidatefrozen as drug constituents and forms the drug composite by mixing acceptable accessories pharmaceutically; the preparation method is that: the salt of the methylphenidatefrozen is taken as raw material, the accessories with specific kinds and proportion are added, and the dry powder preparation for intravenous injection is prepared and developed by adopting the illustrative technological measures. The dry powder preparation is used for treating attention deficiency hyperkinetic disorder (hyperkinetic syndrome of children and mild brain functional maladjustment), and eliminating somnolence, lassitude and respiratory depression caused by soporifics.

The invention discloses an American cockroach medicinal composition for curing gastritis and peptic ulcers. The medicinal composition is mainly prepared from an active ingredient mixture prepared by mixing an American cockroach extract and omeprazole. The weight part ratio of the American cockroach extract to the omeprazole is equal to 0.8-1.2g: 0.33-80mg. A preparation method of the American cockroach medicinal composition for curing the gastritis and the peptic ulcers comprises the following steps of: preparing the American cockroach extract, mixing active ingredients, and preparing medicaments. The medicinal composition has simple preparation method, fully exerts effects of the American cockroach extract, and effectively improves curative effects on the gastritis and the peptic ulcers. The American cockroach medicinal composition has no responses such as headache, diarrhea, astriction, stomachache, sicchasia, emesis skin eruption, dizziness, somnolence and insomnia and the like, and basically does not increase transaminase or bilirubin.

This invention is related to a novel method of treating the chemotoxic effects on the central nervous system of chemotherapeutic drugs, namely Adriamycin, by administering a therapeutically effective amount of anti-Tumor Necrosis Factor-α antibody to a patient to alleviate the symptoms of the effects. The antibody operates to decrease the serum level of Tumor Necrosis Factor-α, prevents the p53 translocation to mitochondria and prevents the decline in mitochondrial respiration of brain tissues and thereby relieves the symptoms of somnolence caused by chemotherapeutic drugs.

The invention provides a use of ferulic acid in preparation of a drug for resisting mammal anxiety and provides a novel antianxiety drug having good effects and small side effects. Ferulic acid is an effective component of the antianxiety drug. Results of mouse elevated plus-maze test, hole-board test and spontaneous activity test on ferulic acid shows that ferulic acid has substantial antianxiety effects and no calmness effect and thus adverse reactions such as fatigue and somnolence caused by calmness effects of the existing antianxiety drug are avoided.

The invention provides a peony extract-methotrexate composition, a preparation method thereof and use thereof. The peony extract-methotrexate composition is prepared from a peony extract and methotrexate and has a better rheumatoid treatment effect than methotrexate and the mixture of the methotrexate and total glucosides of paeony. Meanwhile, the composition can reduce or avoid adverse reactions caused by the methotrexate, such as liver damage, somnolence, inappetence and the like.

The invention relates to a Chinese herbal medicine, in particular to a medicine for clearing heat and calming nerves and a preparation method thereof. The medicine comprising the following ingredients: 5-30 weight portions of polygala root, 5-30 weight portions of amber, 5-40 weight portions of oyster, 1-15 weight portions of magnetite (calcined), 5-30 weight portions of Chinese magnoliavine, 1-15 weight portions of Ligusticum wallichii, 5-30 weight portions of chrysanthemum, 5-30 weight portions of Chinese angelica, 5-40 weight portions of keel (calcined), 5-30 weight portions of irkutsk anemone rhizome, 5-30 weight portions of rehmannia glutinosa, 5-30 weight portions of salvia miltiorrhiza, 5-30 weight portions of tuber of dwarf lilyturf, 1-15 weight portions of licorice, 5-40 weight portions of polygonatum odoratum, 5-30 weight portions of cape jasmine, 5-20 weight portions of scutellaria baicalensis, 1-15 weight portions of vine of multiflower knotweed, and 1-15 weight portions of Celastrus orbiculatus Thunb. The medicine disclosed in the invention processed by extraction and purification has high medicine component contents, little medicine dosage and strict quality control indexes, and achieves the requirements of safety and efficiency, controllable quality and convenient taking. The medicine provided by the invention can be taken for a long time without adverse reactions of listlessness, absentmindedness, somnolence and the like.

An apparatus and method for detecting undiagnosed sleep disordered breathing uses daytime sleepiness and nighttime Obstructive Sleep Apnea (OSA) severity. This involves detecting people with excessive daytime sleepiness (and high likelihood of falling asleep during the day) caused by OSA through objective and subjective daytime and nighttime monitoring. Screening is provided for those who are most likely to be suffering a daytime impact of their sleep apnea and thus most likely to respond positively to a potential diagnosis, and notifying these people is also provided.

The invention discloses traditional Chinese medicine health tea. The traditional Chinese medicine health tea is prepared from the following raw materials in parts by weight: 50-70 parts of roses, 50-70 parts of jasmine flowers, 50-70 parts of seville orange flowers, 50-70 parts of lotus leaves, 30-50 parts of wolfberry fruits and 5-20 parts of dried orange peel. The traditional Chinese medicine health tea adopts common medicinal and edible traditional Chinese medicines as raw materials, is safe and reliable, has no toxic and side effects and no injury to the digestive system and the absorptionsystem of a human body, can give full play to medicinal effects of every traditional Chinese medicine component by compatible application of the raw materials and has the efficacies of beautifying skin, reducing lipid, producing a refreshing effect, regulating the flow of qi, relieving stagnation, resolving phlegm and removing dampness by diuresis. Honey in the traditional Chinese medicine healthtea is mainly used for flavoring and added on the preference of drinkers. The traditional Chinese medicine health tea is capable of promoting normal metabolism of a human body, has obvious weight reducing effects and also has good efficacies of regulating the flow of qi, relieving stagnation, resolving phlegm and removing dampness by diuresis on patients who have fatty liver disease due to accumulation of phlegm-dampness in the body and have the following clinical manifestations: fat body, dull pain in chest and hypochondrium, dizziness, choking sensation in chest, somnolence, tiredness and the like.

The ophthalmic lens includes a substrate, the substrate having a rear face and a front face, and at least one external interferential coating, the at least one interferential coating being such that it enables to selectively reflect light arriving on the rear face with a local maximum of reflection of at least 10% for a wavelength within the range between 450 nm and 490 nm.

The invention belongs to the technical field of food, and in particular relates to a middle-aged and elderly health-care food for improving sleep and protecting eyesight and a preparation method thereof. The formula of the middle-aged and elderly health-care food for improving sleep and protecting eyesight comprises the following components by weight percent: 5-10 percent of xanthophyll, 20-50 percent of Ganoderma atrum extract, 1-5 percent of melatonin and 20-50 percent of grassleaf sweelflag rhizome extract. The formula is scientific and reasonable, has the functions of calming the mind and nerves, relieving anxiety, promoting sleep, and improving sleep quality, and can not cause dizzness, somnolence and addiction which are caused by common drugs after awaking. In addition, the health-care food also has the effects of relieving asthenopia and hypopsia caused by insomnia, improving blurred vision and protecting the eyesight.

A process for preparing Chinese medicing "Pingwei particles" for treating distension of gastral cavity, anorexia, vomiting, nausea, somnolence, etc includes such steps as pulverizing liquorice root, decocting 3 Chinese-medicinal materials including atractyldes rhizome to obtain volatile oil, mixing the volatile oil with cyclodextrin, concentrating the decoction, drying, adding additive, mixing all together, granulating and loading in capsules. Its advantage is high curative effect and safety.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine for treating somnolence caused by yang-qi deficiency. The traditional Chinese medicine is prepared from 10-20 g of cynomorium songaricum, 10-20 g of evodia, 8-18 g of cibotium barometz, 8-18 g of epimedium, 8-18 g of coix seeds, 8-18 g of gordon euryale seeds, 8-18 g of curculigo orchioides, 8-18 g of radix astragali preparata, 8-18 g of rhizoma chuanxiong, 8-18 g of radix aconite lateralis preparata, 5-15 g of aralia chinensis L., 5-15 g of poria cocos, 5-15 g of astragalus complanatus bunge, 5-15 g of radix cynanchi panicullati, 3-9 g of fructus xanthii, 2-10 g of radix codonopsis, 2-10 g of atractylodes macrocephala koidz, 2-10 g of tangerine peel, 2-10 g of liquorice, 2-10 g of lindera aggregate and 2-10 g of dried ginger. Clinical experiments for treating somnolence caused by yang-qi deficiency show that the cure rate is higher than 95.24% and can reach 99.21% at most, the average cure rate is 97.46%, the total effective rate is 100%, and the traditional Chinese medicine is quite suitable for treating somnolence caused by yang-qi deficiency. In addition, the traditional Chinese medicine is quick in effect and short in cure period, is prepared from pure traditional Chinese machine, and is free of toxic and side effects and free of worries of medicine dependence.

The invention relates to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine for treating blood stasis type somnolence. The traditional Chinese medicine is prepared from the following components by weight: 10-20 g of caulis spatholobi, 10-20 g of radix puerariae, 8-18 g of myrrh, 8-18 g of frankincense, 8-18 g of dalbergia wood, 8-18 g of the root bark of the peony tree, 8-18 g of beautiful sweetgum fruits, 8-18 g of curcuma zedoary, 5-15 g of the seeds of cowherb, 5-15 g of radix curcumae longae, 5-15 g of radix paeoniae rubra, 5-15 g of cassia twig, 5-15 g of radix bupleuri, 5-15 g of hematoxylon, 2-10 g of musk, 2-10 g of clove, 2-10 g of peach kernels, 2-10 g of Armeniaca mume, 2-10 g of radish seeds, 2-10 g of chastetree fruits, 2-10 g of gentiana macrophylla, 2-10 g of salsola ruthenica, 2-10 g of hematoxylon, and 2-10 g of rhizoma chuanxiong. The traditional Chinese medicine has the cure rate higher than 95.35% for the blood stasis type somnolence proved through clinical experiment, the highest cure rate is 100%, the average cure rate is 97.91%, the total effective rate is 100%, and the traditional Chinese medicine is very suitable for treating the blood stasis type somnolence, rapid in taking effect, and short in cure cycle; the traditional Chinese medicine composition is prepared from pure traditional Chinese medicinal materials, is free of toxic and side effects, and is free of the trouble of drug dependence.